The Relationship Between Coagulation Tests and Stage in Lung Cancer Patients

Yılmaz Rakıcı, Sema; terzi, özlem

The Relationship Between Coagulation Tests and Stage in Lung Cancer Patients

Sema YILMAZ RAKICI, (Recep Tayyip Erdoğan Üniversitesi)

Özlem TERZİ (Ondokuz Mayıs Üniversitesi)

ACTA ONCOLOGICA TURCICA

0 0

Yıl: 2019 Cilt: 52 Sayı: 1 Sayfa Aralığı: 103 - 111 Metin Dili: İngilizce İndeks Tarihi: 05-12-2019

The Relationship Between Coagulation Tests and Stage in Lung Cancer Patients

Öz:

INTRODUCTION: In this study, the effects of changes in coagulation tests on survival and distant organmetastasis in lung cancer patients were investigated.METHODS: We retrospectively evaluated the data of patients who were diagnosed with primary lung cancer byour radiation oncology clinic. The relationship between age, sex, histopathological diagnosis, metastasis status andcoagulation test values and lifespan were analyzed.RESULTS: A total of 342 patients were included in the study. 18,4% of the patients had small cell lung cancer(SCLC), and 81,6% had non-small cell lung cancer (NSCLC). Adenocarcinoma (45.0%) was the most commonhistopathological subtype in patients with NSCLC. When distant organ metastasis rates were handled for allpatients, while there weren’t distant organ metastasis in 44.4% of patients, distant organ metastasis was found outin 55.6% of the patients. 65.1% of patients with SCLC and 53.4% of patients with SCLC were in advanced stageswith distant organ metastasis. 18.4% of the patients had brain metastasis, and 81.6% had no brain metastasis. Therewas no statistically significant effect of APTT, PT, INR, % PT which are among the coagulation tests, andfibrinogen values on brain metastasis status and survival (p> 0.05). However, in patients with brain metastases,increase in the ratio close to statistical significance the INR and% PT values was found (p = 0.068, p = 0.059,respectively) when compared to the non-men.DISCUSSION AND CONCLUSION: In the case of lung cancer, an increase in the frequency of brain metastasismay be associated with the hypothesis that prolongation of the coagulation test and deterioration of the blood-brainbarrier, but there is a need for extensive studies with more patients.

Anahtar Kelime:

Konular: Tıbbi İnformatik Genel ve Dahili Tıp Temel Sağlık Hizmetleri Onkoloji Sağlık Bilimleri ve Hizmetleri

Akciğer Kanseri Tanılı Hastalarda Koagülasyon Test Değerlerinin Tanı Anındaki Evreyle İlişkisi

Öz:

GİRİŞ ve AMAÇ: Bu çalışmada akciğer kanserli hastalarda koagulasyon testlerindeki değişikliklerin sağkalım ve uzak organ metastazı üzerine etkisi araştırıldı. YÖNTEM ve GEREÇLER: Çalışmamız, hastanemiz radyasyon onkolojisi kliniğine başvuran primer akciğer kanseri tanısı almış hastaların verileri retrospektif değerlendirilerek yapıldı. Yaș, cinsiyet, histopatolojik tanı, metastaz durumu ile koagulasyon test değerleri ve yaşam süresi arasında ilişki analiz edildi. BULGULAR: Çalışmaya toplam 342 hasta dahil edildi. Hastaların %18.4’ü küçük hücreli akciğer kanseri (KHAK) iken %81.6 küçük hücreli dışı akciğer kanseri (KHAK) tanısına sahipti. KHDAK’li hastalarda en sık görülen histopatolojik alt tip Adenokarsinom (%45.0) idi. Tüm hastalar için uzak organ metastaz oranlarına bakıldığında hastaların %44.4’ünde uzak organ metastazı yokken, %55.6’sında uzak organ metastazı vardı. KHAK’li hastaların %65.1’i, KHDAK’lı hastaların ise %53.4’ü uzak organ metastazı olan ileri evre olgulardı. Hastaların %18.4’ünde beyin metastazı varken, %81.6’sında ise beyin metastazı yoktu. Koagulasyon testlerinden APTT, PT, INR, %PT ve fibrinojen değerlerinin beyin metastazı durumu ve sağkalım üzerine istatistiksel anlamlı etkisi saptanmadı (p>0.05). Ancak beyin metastazı olanlarda, olmayanlarla karşılaştırıldığında INR ve %PT değerlerinde istatiksel olarak anlamlılığa yakın oranda artış tespit edildi (sırasıyla p=0.068, p=0.059). TARTIŞMA ve SONUÇ: Akciğer kanseri olgularında koagulasyon testlerindeki uzama ile kan beyin bariyerinin de bozulduğu hipotezi ile ilişkili olarak beyin metastazı sıklığında artış oluşabilir ancak daha fazla hasta sayısının olduğu geniş kapsamlı çalışmalara ihtiyaç vardır.

Anahtar Kelime:

Konular: Tıbbi İnformatik Genel ve Dahili Tıp Temel Sağlık Hizmetleri Onkoloji Sağlık Bilimleri ve Hizmetleri

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Gültekin M, Boztaş G. Türkiye kanser istatistikleri. Sağlık Bakanlığı, Türkiye Halk Sağlığı Kurumu. 2014; 43.
Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. International Early Lung Cancer Action Program Investigators. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006; 355: 1763-71.
Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. JAMA. 2007; 297: 953-61.
Köktürk N, Yeğin D, Çiftçi UT, Mullaoğlu BS, Öztürk C. Akciğer kanserlerinde epidemiyolojik özellikler yıllar içinde değişim gösteriyor mu? Toraks Dergisi. 2004; 5: 137-42.
Lung and Pleural Malignancies Study Group. Pattern of lung cancer in Turkey 1994-1998. Turkish Thoracic Society. Respiration. 2002; 69: 207-10.
TC sağlık bakanlığı Türkiye halk sağlığı kurumu kanser istatistikleri. Ankara 2017. http://kanser.gov.tr/daire-faaliyetleri/kanseristatistikleri.
Spiro SG, Porter JC. Lung cancer-Where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med. 2002; 166: 1166-96.
Skuladottir H, Olsen JH, Hirsch FR. Incidence of lung cancer in Denmark: historical and actual status. Lung Cancer. 2000; 27: 107-18.
Cha Q, Chen Y, Du Y. The trends in histological types of lung cancer during 1980-1988, Guangzhou, China. Lung Cancer. 1997; 17: 219-30.
Meert AP, Paesmans M, Berghmans T, Martin B, Mascaux C, Vallot F, et al. Prophylactic cranial irradiation in small cell lung cancer: A systematic review of the literature with meta-analysis. BMC Cancer. 2001; 1: 5.
Altman E, Cadman E. Analysis of 1539 patients with cancer of unknown primary site. Cancer. 1986; 57: 120-4.
Kömürcüoğlu A, Kömürcüoğlu B, Konya A, Ediboğlu H, Utkaner G, Çelikten E, ve ark. Beyin metastazı semptomları ile ortaya çıkan akciğer kanserleri. Solunum Hastalıkları. 2003; 14: 41-5.
Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol. 2005; 167: 913–20.
El Kamar FG, Posner JB. Brain metastases. Semin Neurol. 2004; 24: 347–62.
Arshad F, Lili Wang L, Sy C, Avraham S, Avraham HK. Blood-Brain Barrier Integrity and Breast Cancer Metastasis to the Brain. Patholog Res Int. 2011; 2011:1-12.
Labelle M, Hynes RO. The initial hours of metastasis the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov. 2012; 2: 1091–9.
van Zijl F, Krupitza G, Mikulits W. Initial steps of metastasis cell invasion and endothelial transmigration. Mutat Res. 2011; 728: 23–34.
Nguyen DX, Bos PD, Massague J. Metastasis from dissemination to organ-specific colonization. Nat Rev Cancer. 2009; 9: 274–84.
Bos PD, Nguyen DX, Massague J. Modeling metastasis in the mouse. Curr Opin Pharmaco. 2010; 10: 571–77.
Wilhelm I, Molnar J, Fazakas C, Hasko J, Krizbai IA. Role of the blood-brain barrier in the formation of brain metastases. Int J Mol Med Sci. 2013; 14: 1383- 411.
Jia W, Lu R, Martin TA, Jiang WG. The role of claudin-5 in blood-brain barrier (BBB) and brain metastases. Mol Med Rep. 2014; 9: 779-85.
Strell C, Entschladen F. Extravasation of leukocytes in comparison to tumor cells. Cell Commun Signal. 2008; 6: 10.
Germano AF, Tomasello F. Blood-brain barrier permeability changes after subarachnoid haemorrhage: an update. Clinical implications, experimental findings, challenges and future directions. New York: Springer-Verlag Wien; 2001: 5-18.
Fenstermacher JD, Rapaport ST. Blood brain barrier. In Handbook of Physiology - The Cardiovascular System. 4 th ed. New York: American Physiological Society. 1984: 969-1000.
Stanness KA, Westrum LE, Fornaciari E, Mascagni P, Nelson JA, Stenglein SG, et al. Morphological and functional characterization of an In vitro blood-brain barrier model. Brain Res. 1997; 771:329-342.
Gültürk S, İmir G, Tuncer E. Kan beyin bariyeri. Erciyes Medical Journal. 2007; 29: 147-154.
Abbott NJ, Mendonca LL, Dolman DE. The bloodbrain barrier in systemic lupus erythematosus. Lupus. 2003; 12: 908- 915.
Kaya M, Gulturk S, Elmas I, Kalayci R, Arican N, Kocyildiz ZC, et al. The effects of magnesium sulfate on blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats. Life Sci. 2004; 76: 201-12.
Mark KS, Davis TP. Cerebral microvascular changes in permeability and tight junctions induced by hypoxiareoxygenation. Am J Physiol Heart Circ Physiol. 2002; 282: 1485-94.
Khuon S, Liang L, Dettman RW, Sporn PH, Wysolmerski RB, Chew TL. Myosin light chain kinase mediates transcellular intravasation of breast cancer cells through the underlying endothelial cells a three-dimensional FRET study. J Cell Sci. 2010; 123: 431–8.
Reymond N, d’Agua BB, Ridley AJ. Crossing the endothelial barrier during metastasis. Nat Rev Cancer. 2013; 13: 858–8.
Leong H.S, Robertson AE, Stoletov K, Leith SJ, Chin CA, Chien, AE, et al. Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis. Cell Rep. 2014; 8: 1558–8.
Wolburg H, Lippoldt A.Tight junctions of the blood– brain barrier: development, composition and regulation. Vascul Pharmacol. 2002; 38: 323-37.
Abbott NJ, Ronnback L, Hansson E.Astrocyte– endothelial interactions at the blood–brain barrier Nature Rev Neurosci. 2006; 7: 41-53.

APA	Yılmaz Rakıcı S, terzi ö (2019). The Relationship Between Coagulation Tests and Stage in Lung Cancer Patients. , 103 - 111.
Chicago	Yılmaz Rakıcı Sema,terzi özlem The Relationship Between Coagulation Tests and Stage in Lung Cancer Patients. (2019): 103 - 111.
MLA	Yılmaz Rakıcı Sema,terzi özlem The Relationship Between Coagulation Tests and Stage in Lung Cancer Patients. , 2019, ss.103 - 111.
AMA	Yılmaz Rakıcı S,terzi ö The Relationship Between Coagulation Tests and Stage in Lung Cancer Patients. . 2019; 103 - 111.
Vancouver	Yılmaz Rakıcı S,terzi ö The Relationship Between Coagulation Tests and Stage in Lung Cancer Patients. . 2019; 103 - 111.
IEEE	Yılmaz Rakıcı S,terzi ö "The Relationship Between Coagulation Tests and Stage in Lung Cancer Patients." , ss.103 - 111, 2019.
ISNAD	Yılmaz Rakıcı, Sema - terzi, özlem. "The Relationship Between Coagulation Tests and Stage in Lung Cancer Patients". (2019), 103-111.

APA	Yılmaz Rakıcı S, terzi ö (2019). The Relationship Between Coagulation Tests and Stage in Lung Cancer Patients. ACTA ONCOLOGICA TURCICA, 52(1), 103 - 111.
Chicago	Yılmaz Rakıcı Sema,terzi özlem The Relationship Between Coagulation Tests and Stage in Lung Cancer Patients. ACTA ONCOLOGICA TURCICA 52, no.1 (2019): 103 - 111.
MLA	Yılmaz Rakıcı Sema,terzi özlem The Relationship Between Coagulation Tests and Stage in Lung Cancer Patients. ACTA ONCOLOGICA TURCICA, vol.52, no.1, 2019, ss.103 - 111.
AMA	Yılmaz Rakıcı S,terzi ö The Relationship Between Coagulation Tests and Stage in Lung Cancer Patients. ACTA ONCOLOGICA TURCICA. 2019; 52(1): 103 - 111.
Vancouver	Yılmaz Rakıcı S,terzi ö The Relationship Between Coagulation Tests and Stage in Lung Cancer Patients. ACTA ONCOLOGICA TURCICA. 2019; 52(1): 103 - 111.
IEEE	Yılmaz Rakıcı S,terzi ö "The Relationship Between Coagulation Tests and Stage in Lung Cancer Patients." ACTA ONCOLOGICA TURCICA, 52, ss.103 - 111, 2019.
ISNAD	Yılmaz Rakıcı, Sema - terzi, özlem. "The Relationship Between Coagulation Tests and Stage in Lung Cancer Patients". ACTA ONCOLOGICA TURCICA 52/1 (2019), 103-111.